Envista (NYSE:NVST) Stock Bumped Down to “Hold” by Wall Street Zen

Wall Street Zen downgraded shares of Envista (NYSE:NVST) from a buy rating to a hold rating in a research note released on Saturday morning,Wall Street Zen reports.

Several other equities research analysts have also commented on the stock. Leerink Partners reduced their price target on shares of Envista from $35.00 to $32.00 and set an “outperform” rating for the company in a report on Wednesday, October 14th. Deutsche Bank Aktiengesellschaft set a $32.00 price objective on shares of Envista in a research note on Thursday, September 3rd. Mizuho set a $29.00 price objective on shares of Envista in a report on Thursday, August 6th. Piper Sandler reduced their price objective on shares of Envista from $28.00 to $26.00 and set a “neutral” rating for the company in a research note on Friday, October 9th. Finally, JPMorgan Chase & Co. upgraded Envista from a “neutral” rating to an “overweight” rating and upped their target price for the stock from $29.00 to $32.00 in a report on Thursday, September 3rd. Six investment analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $29.00.

Envista Stock Performance

NVST stock opened at $25.20 on Friday. The company has a debt-to-equity ratio of 0.46, a current ratio of 2.45 and a quick ratio of 2.07. The business has a 50-day moving average price of $24.38 and a 200 day moving average price of $25.74. The company has a market capitalization of $4.05 billion, a P/E ratio of 6.51, a PEG ratio of 1.27 and a beta of 0.94. Envista has a 1-year low of $18.77 and a 1-year high of $30.42.

Envista (NYSE:NVST) last released its quarterly earnings data on Wednesday, November 4th. The company reported $0.40 earnings per share for the quarter, topping analysts’ consensus estimates of $0.36 by $0.04. Envista had a net margin of 22.01% and a return on equity of 8.26%. The company had revenue of $691.50 million during the quarter, compared to analyst estimates of $688.74 million. During the same period in the prior year, the firm earned $0.32 earnings per share. The firm’s revenue for the quarter was up 3.2% compared to the same quarter last year. As a group, equities research analysts forecast that Envista will post 1.56 EPS for the current fiscal year.

Insider Buying and Selling

In other Envista news, SVP Mischa Reis sold 8,000 shares of the stock in a transaction dated Thursday, August 20th. The shares were sold at an average price of $27.50, for a total transaction of $220,000.00. Following the completion of the sale, the senior vice president directly owned 27,321 shares of the company’s stock, valued at approximately $751,327.50. This represents a 22.65% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.99% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of NVST. Arrowstreet Capital Limited Partnership raised its stake in Envista by 341.5% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 2,858,293 shares of the company’s stock worth $72,515,000 after acquiring an additional 2,210,847 shares during the last quarter. Wellington Management Group LLP grew its stake in Envista by 2,662.1% during the 2nd quarter. Wellington Management Group LLP now owns 1,686,415 shares of the company’s stock valued at $44,437,000 after purchasing an additional 1,625,360 shares during the last quarter. Bank of New York Mellon Corp purchased a new stake in Envista during the 2nd quarter valued at about $37,316,000. Pzena Investment Management LLC acquired a new position in shares of Envista in the second quarter valued at about $30,494,000. Finally, Renaissance Technologies LLC increased its holdings in shares of Envista by 195.9% in the first quarter. Renaissance Technologies LLC now owns 1,208,165 shares of the company’s stock valued at $30,651,000 after purchasing an additional 799,900 shares during the period.

Key Stories Impacting Envista

Here are the key news stories impacting Envista this week:

• Positive Sentiment: Q3 results topped expectations: Envista reported adjusted earnings of $0.40 per share and revenue of $691.5 million, both above analyst estimates. Revenue rose 3.2% year over year, while earnings increased from $0.32 a year earlier. Envista tops Q3 earnings and revenue estimates
• Positive Sentiment: 2026 outlook raised: Management lifted its earnings outlook, citing pricing and productivity gains—an encouraging signal for near-term profitability. Q3 earnings-call highlights
• Positive Sentiment: UBS raised its price target from $27 to $29, though it maintained a Neutral rating. UBS Group stock recommendations
• Neutral Sentiment: Some valuation commentary argues NVST may be undervalued following a substantial prior decline, while a Zacks article highlights its momentum score. These are analyst perspectives rather than new company developments. Envista could be undervalued on earnings guidance
• Negative Sentiment: China remains a forward-looking risk: Procurement reforms there could weigh on margins as Envista enters 2027, potentially offsetting some benefits from pricing and productivity improvements. Q3 earnings-call highlights

About Envista

Envista Holdings Corporation (NYSE: NVST) is a global dental products and technologies company headquartered in Brea, California. The company develops, manufactures and markets products used by dentists, dental specialists, dental laboratories and other oral health professionals.

Envista’s portfolio includes dental implants, orthodontic systems, digital imaging and workflow solutions, dental consumables, treatment equipment and related technologies. Its brands include Nobel Biocare, Ormco, DEXIS and Kerr, which provide products and services spanning implant dentistry, orthodontics, diagnostic imaging, restorative care and general dental practice management.

Envista was established as an independent public company in 2019 following its separation from Danaher Corporation.